We recently compiled a list of the 8 Best American Dividend Stocks To Buy Right Now. In this article, we are going to take a ...

Pfizer has had its own issues with falling Covid-19 vaccine sales weighing on its stock performance over the recent years.

Pfizer has a diversified portfolio, including successful vaccines and promising new drugs. Read more to see why I upgrade PFE ...

Today, Benzinga 's options scanner spotted 29 uncommon options trades for Pfizer. This isn't normal. The overall sentiment of ...

In a report released today, Umer Raffat from Evercore ISI maintained a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...

Currently, Pfizer has a Zacks Rank of #2 (Buy), while Novo Nordisk has a Zacks Rank of #3 (Hold). This means that PFE's earnings estimate revision activity has been more impressive, so investors ...

Pfizer (PFE) closed the latest trading day at $25.23, indicating a -1.33% change from the previous session's end. The stock's change was less than the S&P 500's daily gain of 0.82%. Meanwhile, the Dow ...

The murder of Brian Thompson, the CEO of UnitedHealth's insurance arm, ignited an outpouring of anger from Americans ...

On Tuesday, Pfizer Inc (PFE) stock saw a decline, ending the day at $25.57 which represents a decrease of $-0.53 or -2.03% from the prior close of $26.1. The stock opened at $26.1 and touched a low of ...

With the economy showing mixed growth signals and changing federal policies, buying high-yielding dividend stocks could be a ...

Guggenheim lowered the firm’s price target on Pfizer (PFE) to $33 from $35 and keeps a Buy rating on the shares. Pfizer will be releasing their ...

The healthcare industry thrives due to novel drug pipeline discoveries, AI integration to streamline processes and ...